The annual event brings together basic scientists, clinical researchers, early career investigators, clinicians and the care research community to discuss the latest developments and innovation in Alzheimer’s and dementia research.
With only a fifth of WHO Member States meeting their commitments to the Global Action Plan on dementia, urgent action is needed to address the escalating global dementia crisis.
In this blog, the World Alzheimer Report 2020 authors discuss the creation of a new national dementia plan guide which aims to aid policymakers and interested people looking to include dementia-related design in their own national dementia plans.
In this blog, Amalia Fonk-Utomo writes about her experience as Head of Accreditation and the journey to Kiang Wu Nursing College of Macau becoming the first ADI Accredited body.
ADI delivered important statements to the World Health Organization (WHO) and Member States on the importance of considering those living with dementia and carers in pandemic responses, humanitarian crises, as well as a new neurological global action plan.
In this blog from Maree McCabe, CEO of Dementia Australia, Maree writes about the organisation's dementia friendly communities programme and how people living with dementia are spearheading its success.
The Centers for Medicare & Medicaid Services (CMS) in the US confirms requirement for clinical trials to access Aduhelm but broadens which trials are eligible.
The study by Institute for Health Metrics and Evaluation (IHME) published in The Lancet predicts 153 million people will be living with Alzheimer’s disease by 2050.
This follows the result of the negative vote trend by the Committee for Medicinal Products for Human Use (CHMP) at their oral explanation meeting in November.
As 2021 comes to an end, ADI CEO Paola Barbarino reflects on the work of ADI in 2021 and what we are looking towards to in 2022.